Stay Engaged
News & Updates
Welcome to our News & Updates page, where you can find the latest information and insights on our journey towards Here, we share exciting news, scientific breakthroughs, and updates on our ongoing projects. Stay connected with us to stay informed about the latest developments, upcoming events, and important announcements. Explore our news articles and discover how we are making significant strides towards improving the lives of those affected by Parkinson’s disease.
22.04.2025 – FUNDING
Parkinnova Secures €350,000 in Funding from Innovatiefonds Noord-Holland
We’re proud to announce that Parkinnova Therapeutics has secured €350,000 in funding from Innovatiefonds Noord-Holland. With this funding, we will advance the optimization of our most promising compounds and perform key preclinical studies to validate efficacy and safety — moving one step closer to clinical trials and a new era of Parkinson’s treatment. We’re grateful to Innovatiefonds Noord-Holland for supporting our mission to redefine how Parkinson’s is treated.
18.12.2024 – FUNDING
Parkinnova Secures €250,000 Through NWO Take Off 2 Program
We are excited to announce that Parkinnova Therapeutics has been awarded €250,000 in funding through the Take Off 2 program by the Dutch Research Council (NWO). We are honored by the NWO’s recognition of the potential impact of our work and grateful for their support in driving forward groundbreaking medical innovations. This funding brings us one step closer to transforming the lives of millions affected by Parkinson’s worldwide.
13.12.2024 – CONGRESS & SYMPOSIUM
Parkinnova at the 2024 Amsterdam Neuroscience Annual Meeting
Dr. Lars van der Heide, one of our co-founders and CSO represented Parkinnova Therapeutics at the 2024 Amsterdam Neuroscience Annual Meeting. The event, hosted by one of Europe’s largest neuroscience communities, brought together leading researchers and clinicians to advance our understanding of the human brain and nervous system.
25.10.2024 – SCIENCE
New Research Publication in Cell & Bioscience
We are pleased to announce our latest study published in Cell & Bioscience, which explores the therapeutic potential of phosphodiesterase (PDE) inhibition in improving motor function in Parkinson’s disease. Titled “Phosphodiesterase Inhibition and GUCY2C Activation Enhance Tyrosine Hydroxylase Ser40 Phosphorylation and Improve 6-Hydroxydopamine-Induced Motor Deficits”, this study demonstrates how PDE inhibition enhances motor function in Parkinson’s disease by promoting tyrosine hydroxylase Ser40 phosphorylation. This innovative approach offers a promising new direction for Parkinson’s treatment.
25.06.2024 – SCIENCE
New Publication in Trends in Molecular Medicine
We are excited to announce our latest publication in the Cell Press Journal Trends in Molecular Medicine. Our paper titled “Boosting endogenous dopamine production: a novel therapeutic approach for Parkinson’s disease” explores a groundbreaking strategy for treating Parkinson’s disease. This forum-style article focuses on the role of tyrosine hydroxylase Ser40 phosphorylation in enhancing endogenous dopamine production. This innovative approach aims to overcome the limitations of existing therapies by replenishing depleted dopamine stores more effectively, potentially alleviating motor symptoms with fewer side effects and improved long-term outcomes.
30.01.2024 – BUSINESS
Parkinnova Therapeutics Incorporates in collaboration with UvA Ventures Holding
Parkinnova Therapeutics, a pioneering spin-off from the University of Amsterdam led by molecular neuroscience experts Prof. Dr. Marten Smidt and Dr. Lars van der Heide, has officially been established as of January 30, 2024. In collaboration with UvA Ventures Holding BV, the company aims to accelerate the development and commercialization of innovative treatments for Parkinson’s disease, leveraging decades of collective expertise in molecular neuroscience and strategic support. Parkinnova is dedicated to advancing novel therapies that improve the quality of life for individuals affected by Parkinson’s globally.
30.09.2023 – SCIENCE
THE FIRST SCIENTIFIC PAPER FROM PARKINNOVA IS PUBLISHED
Our first scientific research paper is published in the Journal of Neurochemistry. Our work titled “Tyrosine hydroxylase phosphorylation is under the control of serine 40” delves into the regulation of the rate-limiting enzyme in dopamine synthesis: Tyrosine Hydroxylase.
28.01.2021 – PATENT
Parkinnova’s second patent publicly available
Our second patent focused on advancing the treatment of Parkinson’s disease is publicly available. Titled ‘Use of a PDE11 or PDE2 Inhibitor for the Treatment of Parkinson’s Disease,’ this patent encompasses innovative means and methods for addressing the condition. In certain embodiments, it involves the utilization of a PDE2 inhibitor, a PDE11 inhibitor, or a combination thereof, along with the possibility of a GUCY2C agonist. This achievement represents another significant milestone in our ongoing commitment to improving the lives of individuals affected by Parkinson’s.
09.01.2020 – PATENT
Parkinnova’s first patent publicly available
Our patent, titled ‘Specific Increase of Dopamine Synthesis Through Targeting of the Guanylate Cyclase 2C Receptor,’ is now accessible to the public. This patent encompasses novel approaches and techniques for the treatment of Parkinson’s disease. Notably, it involves the utilization of a GUCY2C agonist in certain methodologies. Additionally, the patent highlights the significance of test systems and cells in identifying potential candidate compounds for Parkinson’s disease treatment.
14.03.2019 – MEDIA
Parkinnova’s approach featured in the Pharmaceutical Patent Analyst
Parkinnova’s novel approach to treating Parkinson’s disease has garnered recognition in a recent issue of Pharmaceutical Patent Analyst (Vol. 8, No. 1), which was published online on March 14, 2019. The innovative approach, outlined in Parkinnova’s patent (WO/2018/160067), was prominently featured and described as “a truly novel alternative” to current treatment methods for Parkinson’s disease. This acknowledgment in the Pharmaceutical Patent Analyst magazine highlights the pioneering nature of Parkinnova’s work in addressing the challenges of Parkinson’s disease.